centerforbiosimilars1h
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
JD Supra15h
Transparency Is the Best Medicine: Device Parts Don’t Justify Orange Book Listing
The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
Kennedy’s vaccine sell
A Trump transition savant is helping to guide Robert F. Kennedy Jr. — President-elect Donald Trump’s controversial pick to ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...